Skip to content
Fowler Lab
Fowler Lab

Predicting antibiotic resistance de novo

  • News
  • Research
    • Overview
    • Manifesto
    • Software
    • Reproducibility
    • Publications
  • Members
  • Teaching
  • Contact
    • PhDs
  • Wiki
Fowler Lab
Fowler Lab

Predicting antibiotic resistance de novo

New publication: Reconciling the potentially irreconcilable? Genotypic and phenotypic amoxicillin-clavulanate resistance in Escherichia coli.

Philip Fowler, 30th March 202022nd August 2020

Clinical microbiology often assumes a sample is resistant or susceptible. Making such a classification relies on applying a threshold (usually called a cutoff) to quantitative data, such as minimum inhibitory concentrations (MICs). If the MICs are strongly bimodal, then this is trivial and reproducibility is guaranteed. If the MICs are unimodal, then one is left with the unsatisfactory situation whereby the clinical test does not appear to be reproducible since natural variation can cause individual results to “flip-flop” over the cutoff.

Tim Davies, who led this work (open access), shows that whilst amoxicillin, a beta-lactam antibiotic, has a bimodal MIC distribution, when taken with the beta-lactamase inhibitor clavulanate in the combined therapy co-amoxiclav, the MIC distribution becomes unimodal with all the attendant problems of a lack of reproducibility. This is further complicated by the US and European bodies (CLSI and EUCAST) adopting incompatible testing approaches.

The original aim of this work was the test how well knowing the genetics of an E.coli infection could be used to predict its susceptibility to standard treatments, like co-amoxiclav. Simple presence/absence of beta-lactamase genes is not sufficient; instead the predictive model has to include knowledge of promoter mutations and copy number. Even with these improvements, the above reproducibilty problem ensures there is an upper threshold to the sensitivity/specificity possible.

In other words, translating genetics into clinical microbiology for E.coli is going to be a whole lot harder than it was for M. tuberculosis!

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Bluesky (Opens in new window) Bluesky
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Mastodon (Opens in new window) Mastodon

Related

antimicrobial resistance clinical microbiology publication research

Post navigation

Previous post
Next post

Related Posts

antimicrobial resistance

New preprint: looking at rifampicin-resistant subpopulations in clinical samples

10th April 202510th April 2025

Since clinical samples are usually grown in a MGIT tube for a while before some…

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Bluesky (Opens in new window) Bluesky
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Mastodon (Opens in new window) Mastodon
Read More
antimicrobial resistance

New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis

28th August 201829th September 2018

This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum…

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Bluesky (Opens in new window) Bluesky
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Mastodon (Opens in new window) Mastodon
Read More
antimicrobial resistance

BashTheBug reaches one million classifications

4th October 20184th October 2018

  BashTheBug, a citizen science project I run that is helping us measure how different…

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Bluesky (Opens in new window) Bluesky
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Mastodon (Opens in new window) Mastodon
Read More

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy
    ©2025 Fowler Lab | WordPress Theme by SuperbThemes
     

    Loading Comments...